LON:DXRX Diaceutics (DXRX) Share Price, News & Analysis GBX 182 -8.00 (-4.21%) As of 11/20/2026 12:33 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and Trends About Diaceutics Stock (LON:DXRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Diaceutics alerts:Sign Up Key Stats Today's Range 182▼ 19550-Day Range 158.55▼ 206.5052-Week Range 125▼ 210Volume465,131 shsAverage Volume298,615 shsMarket Capitalization£154.65 millionP/E RatioN/ADividend YieldN/APrice TargetGBX 215Consensus RatingBuy Company Overview At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®. Read More Diaceutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks27th Percentile Overall ScoreDXRX MarketRank™: 1.35832521908 of 5 starsDiaceutics scored higher than 27% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingBuy Consensus RatingDiaceutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and no sell ratings.Upside PotentialDiaceutics has a consensus price target of GBX 215, representing about 18.1% upside from its current price of GBX 182.Amount of Analyst CoverageDiaceutics has only been the subject of 1 research reports in the past 90 days.Read more about Diaceutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Diaceutics is -568.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Diaceutics is -568.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDiaceutics has a P/B Ratio of 3.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for DXRX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDiaceutics does not currently pay a dividend.Dividend GrowthDiaceutics does not have a long track record of dividend growth. News and Social Media0.7 / 5News Sentiment-0.92 News SentimentDiaceutics has a news sentiment score of -0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Diaceutics this week, compared to 0 articles on an average week. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Diaceutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought GBX 0 in company stock and sold £4,940,000 in company stock.Percentage Held by Insiders26.23% of the stock of Diaceutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions32.18% of the stock of Diaceutics is held by institutions.Read more about Diaceutics' insider trading history. Receive DXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Diaceutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DXRX Stock News HeadlinesDiaceutics (LON:DXRX) Stock: Insider Jordan Clark Sells 250,000 SharesNovember 15, 2026 | americanbankingnews.comDiaceutics (LON:DXRX) Stock: Insider Peter Keeling Sells 1,750,000 SharesNovember 15, 2026 | americanbankingnews.comAre Tesla and SpaceX Going Bankrupt?Tesla and SpaceX shares crashed right after Democrats took the House and the Senate in the midterm election. Elon Musk backed President Trump and donated millions to Republicans, and many believe he will become a political target. Brownstone Research founder Jeff Brown has seen Musk's new technology on camera. He says he is more convinced than ever that nothing can stop the coming Elon Musk revolution. | Brownstone Research (Ad)Diaceutics (LON:DXRX) Insider Sells £475,000 in StockNovember 14, 2026 | insidertrades.comCanaccord Genuity Group Reaffirms Buy Rating for Diaceutics (LON:DXRX)November 12, 2026 | americanbankingnews.comDiaceutics (LON:DXRX) Stock Falls 1.4% - Here's WhyNovember 10, 2026 | americanbankingnews.comDiaceutics Updates Employee Share Schemes and Total Shares in IssueOctober 7, 2026 | tipranks.comDiaceutics to Unveil Half-Year 2026 Results and Step Up Investor OutreachSeptember 8, 2026 | tipranks.comSee More Headlines DXRX Stock Analysis - Frequently Asked Questions How have DXRX shares performed this year? Diaceutics' stock was trading at GBX 128 on January 1st, 2026. Since then, DXRX shares have increased by 42.2% and is now trading at GBX 182. How were Diaceutics' earnings last quarter? Diaceutics PLC (LON:DXRX) issued its earnings results on Tuesday, September, 22nd. The company reported GBX (3.27) earnings per share for the quarter. Diaceutics had a negative net margin of 0.66% and a negative trailing twelve-month return on equity of 0.68%. How do I buy shares of Diaceutics? Shares of DXRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. Company Calendar Last Earnings9/22/2026Today11/21/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolLON:DXRX CIKN/A Webwww.diaceutics.com PhoneN/AFaxN/AEmployees151Year FoundedN/APrice Target and Rating Average Price Target for DiaceuticsGBX 215 High Price TargetGBX 215 Low Price TargetGBX 215 Potential Upside/Downside+18.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)GBX (0.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£2.84 million Net Margins-0.66% Pretax MarginN/A Return on Equity-0.68% Return on Assets-6.06% Debt Debt-to-Equity Ratio5.40 Current Ratio2.55 Quick Ratio9.92 Sales & Book Value Annual Sales£41.33 million Price / Sales3.74 Cash FlowGBX 58.34 per share Price / Cash Flow3.12 Book ValueGBX 45.87 per share Price / Book3.97Miscellaneous Outstanding Shares84,972,000Free FloatN/AMarket Cap£154.65 million OptionableNot Optionable Beta0.88 Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (LON:DXRX) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersElon masterplan could turn $500 into half a millionJeff Brown called Tesla an AI company in 2018, when Wall Street said it was going bankrupt. The stock has been...Brownstone Research | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Diaceutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Diaceutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.